These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12149620)

  • 1. Mutant huntingtin goes straight to the heart.
    Cattaneo E; Calabresi P
    Nat Neurosci; 2002 Aug; 5(8):711-2. PubMed ID: 12149620
    [No Abstract]   [Full Text] [Related]  

  • 2. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines.
    Panov AV; Gutekunst CA; Leavitt BR; Hayden MR; Burke JR; Strittmatter WJ; Greenamyre JT
    Nat Neurosci; 2002 Aug; 5(8):731-6. PubMed ID: 12089530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurodegeneration. Huntington's research points to possible new therapies.
    Marx J
    Science; 2005 Oct; 310(5745):43-5. PubMed ID: 16210515
    [No Abstract]   [Full Text] [Related]  

  • 4. Depletion of CBP is directly linked with cellular toxicity caused by mutant huntingtin.
    Jiang H; Poirier MA; Liang Y; Pei Z; Weiskittel CE; Smith WW; DeFranco DB; Ross CA
    Neurobiol Dis; 2006 Sep; 23(3):543-51. PubMed ID: 16766198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
    Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
    Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild type Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models of Huntington's disease.
    Ho LW; Brown R; Maxwell M; Wyttenbach A; Rubinsztein DC
    J Med Genet; 2001 Jul; 38(7):450-2. PubMed ID: 11432963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Huntington's disease.
    Davies S; Ramsden DB
    Mol Pathol; 2001 Dec; 54(6):409-13. PubMed ID: 11724916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant protein in Huntington disease is resistant to proteolysis in affected brain.
    Dyer RB; McMurray CT
    Nat Genet; 2001 Nov; 29(3):270-8. PubMed ID: 11600884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release.
    Choo YS; Johnson GV; MacDonald M; Detloff PJ; Lesort M
    Hum Mol Genet; 2004 Jul; 13(14):1407-20. PubMed ID: 15163634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease.
    Brustovetsky N; LaFrance R; Purl KJ; Brustovetsky T; Keene CD; Low WC; Dubinsky JM
    J Neurochem; 2005 Jun; 93(6):1361-70. PubMed ID: 15935052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease.
    Panov AV; Burke JR; Strittmatter WJ; Greenamyre JT
    Arch Biochem Biophys; 2003 Feb; 410(1):1-6. PubMed ID: 12559971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons.
    Anne SL; Saudou F; Humbert S
    J Neurosci; 2007 Jul; 27(27):7318-28. PubMed ID: 17611284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal and mutant huntingtin: partners in crime.
    Di Prospero NA; Tagle DA
    Nat Med; 2000 Nov; 6(11):1208-9. PubMed ID: 11062523
    [No Abstract]   [Full Text] [Related]  

  • 14. Paradoxical aggregation versus oligomerisation properties of mutant and wild-type huntingtin fragments.
    Rubinsztein DC; Huntington JA
    Exp Neurol; 2006 Jun; 199(2):243-4. PubMed ID: 16631742
    [No Abstract]   [Full Text] [Related]  

  • 15. Mutant huntingtin enhances excitotoxic cell death.
    Zeron MM; Chen N; Moshaver A; Lee AT; Wellington CL; Hayden MR; Raymond LA
    Mol Cell Neurosci; 2001 Jan; 17(1):41-53. PubMed ID: 11161468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between BDNF Val66Met polymorphism and age at onset in Huntington disease.
    Alberch J; López M; Badenas C; Carrasco JL; Milà M; Muñoz E; Canals JM
    Neurology; 2005 Sep; 65(6):964-5. PubMed ID: 16186551
    [No Abstract]   [Full Text] [Related]  

  • 17. Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.
    Han I; You Y; Kordower JH; Brady ST; Morfini GA
    J Neurochem; 2010 Jun; 113(5):1073-91. PubMed ID: 20236390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
    Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
    J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease.
    Trushina E; Heldebrant MP; Perez-Terzic CM; Bortolon R; Kovtun IV; Badger JD; Terzic A; Estévez A; Windebank AJ; Dyer RB; Yao J; McMurray CT
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12171-6. PubMed ID: 14527999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Huntingtin processing in pathogenesis of Huntington disease.
    Qin ZH; Gu ZL
    Acta Pharmacol Sin; 2004 Oct; 25(10):1243-9. PubMed ID: 15456523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.